Join to View Full Profile
160 E 32nd St2nd FloorNew York, NY 10016
Phone+1 212-974-3009
Fax+1 212-974-1042
Dr. Rubenstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Allan Rubenstein is a neurologist located in New York, NY. He completed his medical education at Tufts University School of Medicine and postdoctoral training in internal medicine and neurology at Harlem Hospital Center and New York Presbyterian Hospital, respectively. Dr. Rubenstein has experience in neurogenetics and pediatric neuro-oncology, and has served as Chairman at NexGenix Pharmaceuticals from 2003-2011 and CalAsia Pharmaceuticals from 2012-2014. His research include neurofibromatosis and HSP90 inhibitors, with multiple citations in the medical community.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1971 - 1972
Harlem Hospital CenterInternship, Internal Medicine, 1970 - 1971
Tufts University School of MedicineClass of 1970
Certifications & Licensure
NY State Medical License 1972 - 2025
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- 5 citationsClinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.Lisa Oliveira, Mauro Geller, Karin Soares Gonçalves Cunha, Alessandra Santos, Allan Bernacchi
Heliyon. 2021-03-01 - Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age GroupAlessandra Santos, Mauro Geller, Spyros G.E. Mezitis, Allan E. Rubenstein, Lisa Oliveira
Clinical Pathology. 2020-10-19 - 22 citationsA novel small molecule HSP90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivoJieun R. C. Cha, Kyle J. H. St. Louis, Miranda L. Tradewell, Benoit J. Gentil, Sandra Minotti
Cell Stress & Chaperones. 2014-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
